BGI Genomics Co., Ltd. (300676.SZ)
CNY 48.27
(1.3%)
CNY 48.27
(1.3%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.34 Billion CNY | -38.23% |
| 2022 | 7.04 Billion CNY | 4.14% |
| 2021 | 6.76 Billion CNY | -19.42% |
| 2020 | 8.39 Billion CNY | 199.86% |
| 2019 | 2.8 Billion CNY | 10.41% |
| 2018 | 2.53 Billion CNY | 21.04% |
| 2017 | 2.09 Billion CNY | 22.44% |
| 2016 | 1.71 Billion CNY | 29.79% |
| 2015 | 1.31 Billion CNY | 16.5% |
| 2014 | 1.13 Billion CNY | 8.08% |
| 2013 | 1.04 Billion CNY | 31.77% |
| 2012 | 794.83 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.04 Billion CNY | 27.83% |
| 2024 Q3 | 954.48 Million CNY | -8.69% |
| 2024 Q1 | 817.76 Million CNY | -32.38% |
| 2023 Q3 | 1.07 Billion CNY | -3.99% |
| 2023 FY | 4.35 Billion CNY | -38.23% |
| 2023 Q1 | 953.75 Million CNY | -62.33% |
| 2023 Q2 | 1.11 Billion CNY | 17.13% |
| 2023 Q4 | 1.2 Billion CNY | 12.74% |
| 2022 FY | 7.04 Billion CNY | 4.14% |
| 2022 Q4 | 2.53 Billion CNY | 87.2% |
| 2022 Q3 | 1.35 Billion CNY | -21.87% |
| 2022 Q2 | 1.73 Billion CNY | 21.05% |
| 2022 Q1 | 1.43 Billion CNY | -11.4% |
| 2021 Q2 | 2.08 Billion CNY | 33.23% |
| 2021 Q4 | 1.61 Billion CNY | 7.19% |
| 2021 FY | 6.76 Billion CNY | -19.42% |
| 2021 Q3 | 1.5 Billion CNY | -27.7% |
| 2021 Q1 | 1.56 Billion CNY | -4.97% |
| 2020 FY | 8.39 Billion CNY | 199.86% |
| 2020 Q1 | 791.19 Million CNY | 8.67% |
| 2020 Q2 | 3.31 Billion CNY | 319.19% |
| 2020 Q3 | 2.64 Billion CNY | -20.27% |
| 2020 Q4 | 1.64 Billion CNY | -37.78% |
| 2019 Q4 | 728.04 Million CNY | -6.77% |
| 2019 FY | 2.8 Billion CNY | 10.41% |
| 2019 Q3 | 780.92 Million CNY | 10.19% |
| 2019 Q2 | 708.72 Million CNY | 21.63% |
| 2019 Q1 | 582.71 Million CNY | -19.34% |
| 2018 FY | 2.53 Billion CNY | 21.04% |
| 2018 Q1 | 516.31 Million CNY | -20.43% |
| 2018 Q2 | 624.48 Million CNY | 20.95% |
| 2018 Q3 | 673.14 Million CNY | 7.79% |
| 2018 Q4 | 722.45 Million CNY | 7.33% |
| 2017 Q1 | 387.84 Million CNY | -14.63% |
| 2017 Q2 | 500.38 Million CNY | 29.02% |
| 2017 Q3 | 558.46 Million CNY | 11.61% |
| 2017 Q4 | 648.85 Million CNY | 16.19% |
| 2017 FY | 2.09 Billion CNY | 22.44% |
| 2016 FY | 1.71 Billion CNY | 29.79% |
| 2016 Q4 | 454.28 Million CNY | -7.45% |
| 2016 Q3 | 490.83 Million CNY | 5.93% |
| 2016 Q2 | 463.35 Million CNY | 52.91% |
| 2016 Q1 | 303.02 Million CNY | 0.0% |
| 2015 FY | 1.31 Billion CNY | 16.5% |
| 2015 Q1 | 282.71 Million CNY | 0.0% |
| 2015 Q2 | 282.71 Million CNY | 0.0% |
| 2014 FY | 1.13 Billion CNY | 8.08% |
| 2013 FY | 1.04 Billion CNY | 31.77% |
| 2012 FY | 794.83 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 13.4 Billion CNY | 67.56% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion CNY | 41.094% |
| Dirui Industrial Co.,Ltd. | 1.36 Billion CNY | -219.047% |
| Beijing Strong Biotechnologies, Inc. | 1.74 Billion CNY | -149.746% |
| Medicalsystem Biotechnology Co., Ltd. | 1.88 Billion CNY | -130.644% |
| Maccura Biotechnology Co.Ltd | 2.89 Billion CNY | -50.207% |
| Guangzhou Wondfo Biotech Co.,Ltd | 2.76 Billion CNY | -57.315% |
| Guangdong Hybribio Biotech Co.,Ltd. | 1.1 Billion CNY | -293.827% |
| Amoy Diagnostics Co., Ltd. | 1.03 Billion CNY | -318.703% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1.67 Billion CNY | -159.778% |